These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 1496731)

  • 1. Evaluation of 5.1-[NANP]19, a recombinant Plasmodium falciparum vaccine candidate, in adults.
    Stürchler D; Just M; Berger R; Reber-Liske R; Matile H; Etlinger H; Takacs B; Rudin C; Fernex M
    Trop Geogr Med; 1992 Jan; 44(1-2):9-14. PubMed ID: 1496731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment in humans of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, Plasmodium falciparum.
    Etlinger HM; Felix AM; Gillessen D; Heimer EP; Just M; Pink JR; Sinigaglia F; Stürchler D; Takacs B; Trzeciak A
    J Immunol; 1988 Jan; 140(2):626-33. PubMed ID: 3275719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites.
    Herrington DA; Clyde DF; Losonsky G; Cortesia M; Murphy JR; Davis J; Baqar S; Felix AM; Heimer EP; Gillessen D
    Nature; 1987 Jul 16-22; 328(6127):257-9. PubMed ID: 2439920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha and synthetic peptide malaria sporozoite vaccine in non-immune adults: antibody response after 40 weeks.
    Stürchler D; Zimmer G; Berger R; Etlinger H; Fernex M; Matile H; Just M
    Bull World Health Organ; 1990; 68 Suppl(Suppl):38-41. PubMed ID: 2094589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens.
    Quakyi IA; Otoo LN; Pombo D; Sugars LY; Menon A; De Groot AS; Johnson A; Alling D; Miller LH; Good MF
    Am J Trop Med Hyg; 1989 Aug; 41(2):125-34. PubMed ID: 2672834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral immune responses to the Plasmodium falciparum antigen Pf155 RESA in adults with differential clinical conditions from an Indian zone where malaria is endemic.
    Biswas S; Rao DN; Roy A; Yadav RP; Ghosh SK; Kabilan L
    Southeast Asian J Trop Med Public Health; 1995 Jun; 26(2):219-27. PubMed ID: 8629049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria.
    Patarroyo ME; Amador R; Clavijo P; Moreno A; Guzman F; Romero P; Tascon R; Franco A; Murillo LA; Ponton G
    Nature; 1988 Mar; 332(6160):158-61. PubMed ID: 2450281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [NANP]19-5.1. A malaria vaccine field trial in Nigerian children.
    Reber-Liske R; Salako LA; Matile H; Sowunmi A; Stürchler D
    Trop Geogr Med; 1995; 47(2):61-3. PubMed ID: 8592764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antibody response in mice to carrier-free synthetic polymers of Plasmodium falciparum circumsporozoite repetitive epitope is I-Ab-restricted: possible implications for malaria vaccines.
    Del Giudice G; Cooper JA; Merino J; Verdini AS; Pessi A; Togna AR; Engers HD; Corradin G; Lambert PH
    J Immunol; 1986 Nov; 137(9):2952-5. PubMed ID: 3531341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa.
    Sirima SB; Nébié I; Ouédraogo A; Tiono AB; Konaté AT; Gansané A; Dermé AI; Diarra A; Ouédraogo A; Soulama I; Cuzzin-Ouattara N; Cousens S; Leroy O
    Vaccine; 2007 Mar; 25(14):2723-32. PubMed ID: 17280744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment in mice of a synthetic peptide-based vaccine against the sporozoite stage of the human malaria parasite, P. falciparum.
    Etlinger HM; Heimer EP; Trzeciak A; Felix AM; Gillessen D
    Immunology; 1988 Jul; 64(3):551-8. PubMed ID: 3044983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity, and pilot efficacy of Plasmodium falciparum sporozoite and asexual blood-stage combination vaccine in Swiss adults.
    Sturchler D; Berger R; Rudin C; Just M; Saul A; Rzepczyk C; Brown G; Anders R; Coppel R; Woodrow G
    Am J Trop Med Hyg; 1995 Oct; 53(4):423-31. PubMed ID: 7485698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular and humoral immune responses to a recombinant P. falciparum CS protein in sporozoite-immunized rodents and human volunteers.
    Nardin EH; Nussenzweig RS; Altszuler R; Herrington D; Levine M; Murphy J; Davis J; Bathurst I; Barr P; Romero P
    Bull World Health Organ; 1990; 68 Suppl(Suppl):85-7. PubMed ID: 2094595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
    Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
    Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthetic peptide immunogens eliciting antibodies to Plasmodium falciparum sporozoite and merozoite surface antigens in H-2b and H-2k mice.
    Rzepczyk CM; Csurhes PA; Lord R; Matile H
    J Immunol; 1990 Oct; 145(8):2691-6. PubMed ID: 2212657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune responses to Plasmodium falciparum antigens in children and adults living in a hypoendemic area of Punjab (Pakistan).
    Iqbal J; Rab A; Perlmann P; Berzins K
    Am J Trop Med Hyg; 1994 Oct; 51(4):444-53. PubMed ID: 7943571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.
    Kester KE; McKinney DA; Tornieporth N; Ockenhouse CF; Heppner DG; Hall T; Krzych U; Delchambre M; Voss G; Dowler MG; Palensky J; Wittes J; Cohen J; Ballou WR;
    J Infect Dis; 2001 Feb; 183(4):640-7. PubMed ID: 11170991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity in volunteers of a recombinant Plasmodium falciparum circumsporozoite protein malaria vaccine produced in Lepidopteran cells.
    Herrington DA; Losonsky GA; Smith G; Volvovitz F; Cochran M; Jackson K; Hoffman SL; Gordon DM; Levine MM; Edelman R
    Vaccine; 1992; 10(12):841-6. PubMed ID: 1455910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.